64 related articles for article (PubMed ID: 1615760)
41. Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels.
Cardozo B; Karatza E; Karalis V
Osteoporos Int; 2021 Nov; 32(11):2313-2321. PubMed ID: 34002251
[TBL] [Abstract][Full Text] [Related]
42. On the pharmacological evaluation of bisphosphonates in humans.
Cremers S; Ebetino FH; Phipps R
Bone; 2020 Oct; 139():115501. PubMed ID: 32599224
[TBL] [Abstract][Full Text] [Related]
43. Pharmacology of bisphosphonates.
Cremers S; Drake MT; Ebetino FH; Bilezikian JP; Russell RGG
Br J Clin Pharmacol; 2019 Jun; 85(6):1052-1062. PubMed ID: 30650219
[TBL] [Abstract][Full Text] [Related]
44. Carpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort Study.
Carvajal A; Martín Arias LH; Sáinz M; Escudero A; Fierro I; Sauzet O; Cornelius VR; Molokhia M
PLoS One; 2016; 11(1):e0146772. PubMed ID: 26765346
[TBL] [Abstract][Full Text] [Related]
45. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.
Hayden RS; Vollrath M; Kaplan DL
Acta Biomater; 2014 Jan; 10(1):486-93. PubMed ID: 24096150
[TBL] [Abstract][Full Text] [Related]
46. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
El-Amm J; Freeman A; Patel N; Aragon-Ching JB
Prostate Cancer; 2013; 2013():210686. PubMed ID: 24069538
[TBL] [Abstract][Full Text] [Related]
47. Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature.
Rustemeyer J; Bremerich A
Clin Oral Investig; 2010 Feb; 14(1):59-64. PubMed ID: 19495814
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
Cremers SC; Pillai G; Papapoulos SE
Clin Pharmacokinet; 2005; 44(6):551-70. PubMed ID: 15932344
[TBL] [Abstract][Full Text] [Related]
49. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.
Rosen CJ; Kessenich CR
Drugs; 1996 Apr; 51(4):537-51. PubMed ID: 8706593
[TBL] [Abstract][Full Text] [Related]
50. Bisphosphonates: mechanisms of action.
Rodan GA; Fleisch HA
J Clin Invest; 1996 Jun; 97(12):2692-6. PubMed ID: 8675678
[No Abstract] [Full Text] [Related]
51. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Dunn CJ; Fitton A; Sorkin EM
Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
[TBL] [Abstract][Full Text] [Related]
52. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
53. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
[TBL] [Abstract][Full Text] [Related]
54. Skeletal uptake and lifetime retention of 90Sr and 226Ra in beagles.
Raabe OG; Parks NJ
Radiat Res; 1993 Feb; 133(2):204-18. PubMed ID: 8438062
[TBL] [Abstract][Full Text] [Related]
55. Retention of etidronate in human, dog, and rat.
Kasting GB; Francis MD
J Bone Miner Res; 1992 May; 7(5):513-22. PubMed ID: 1615760
[TBL] [Abstract][Full Text] [Related]
56. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats.
Katsumata T; Nakamura T; Ohnishi H; Sakurama T
J Bone Miner Res; 1995 Jun; 10(6):921-31. PubMed ID: 7572316
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
